Spun out of the Gladstone Institutes - an internationally-known 450 person facility affiliated with the University of California San Francisco and structured around work in the spaces of heart disease, cholesterol metabolism and Alzheimers disease - GABAeron as a start-up biotech company intended to focus specifically on Alzheimers disease. GABAeron is addressing engineered stem cell lines, genetic data and small-molecule drugs ias part of a concerted effort to develop therapeutics to preserve and maybe restore brain function in Alzheimers disease. .
